QIAGEN has announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen® KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
For the fiscal year ended March this year, the company posted a net loss of Rs 56.17 crore. It had posted a net profit of 91.49 crore for the previous fiscal year, the filing said.
Consolidated revenue from operations of the company stood at Rs 1,252.44 crore for the quarter under consideration. It was Rs 1,112.92 crore for the same period a year ago
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Qiagen (QGEN) Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.